Form 4: Candel Therapeutics Executive Seshu Tyagarajan Sells Shares Under 10b5-1 Plan

Seshu Tyagarajan, Chief Technology Officer of Candel Therapeutics, sold 31,278 shares of common stock at an average price of $8.8224 under a pre-arranged 10b5-1 trading plan.

Summary

• On March 17, 2025, Seshu Tyagarajan, the Chief Technology Officer of Candel Therapeutics, sold 31,278 shares of common stock.
• The sale was executed under a 10b5-1 trading plan adopted on November 15, 2024.
• The shares were sold at a weighted average price of $8.8224, with individual transactions ranging from $8.67 to $9.00.
• Following the transaction, Tyagarajan directly owns 85,512 shares of Candel Therapeutics common stock.
• Tyagarajan also holds options to purchase 70,000 shares of common stock, which vest in monthly installments following April 28, 2023.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to an executive's stock sale. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

Executive stock sales are a common occurrence and can be driven by various factors, including personal financial planning. The use of a 10b5-1 trading plan allows insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• The sale does not appear to have any direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Candel Therapeutics, Seshu Tyagarajan, Form 4, Stock Sale, 10b5-1 Trading Plan, Executive Compensation, CADL